Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia

  • Reply to A Coskun and B Oz

    Advances in Nutrition Date published:

  • Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial

    American Journal of Nephrology Date published:

  • Abstract 019: Estimated Benefits And Risks Of Lowering Sodium Through Potassium-enriched Salt Substitution In India: A Modeling Study

    Circulation Date published:

  • EFFECTS OF SALT SUBSTITUTES ON BLOOD PRESSURE AND CLINICAL OUTCOMES IN DIFFERENT POPULATION GROUPS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Journal of the American College of Cardiology Date published:

  • The sodium hidden in medication: a tough pill to swallow

    European Heart Journal Date published:

  • Cardiovascular and Renal Outcomes with Canagliflozin in Patients with Peripheral Artery Disease: Data from the CANVAS program and CREDENCE trials

    Diabetes, Obesity and Metabolism Date published:

  • The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial

    Diabetes & Metabolism Date published:

  • POS-392 CANAGLIFLOZIN TREATMENT IMPACTS COLLAGEN TYPE III DEGRADATION AND FORMATION IN THE CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT STUDY (CANVAS)

    Kidney International Reports Date published:

  • Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin

    Journal of the American College of Cardiology Date published:

  • Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials

    Heart Date published:

  • The effect of salt substitution on headache: a cluster-randomized controlled trial

    Date published:

  • CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL

    Date published:

  • Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA(1c) and predicted risk of kidney failure

    Date published:

  • Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis

    Date published:

  • RESISTANT HYPERTENISION: CLINICAL CHARACTERISTICS AND BLOOD PRESSURE CONTROL

    Date published:

  • Randomized Trials Fit for the 21st Century. A Joint Opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation

    Global Heart Date published: